> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel To Discuss 503A Bulk Drug Additions
- URL: https://www.fdaweb.com/panel-to-discuss-503a-bulk-drug-additions/
- Published: 2024-10-24T12:00:00.000Z
- Updated: 2026-09-14T14:45:01.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158047

*Federal Register* notice: FDA is announcing a 12/4 Pharmacy Compounding Advisory Committee meeting to discuss various bulk drug substances being considered for inclusion on the agency’s 503A bulk drugs listing. Section 503A of the Federal Food, Drug, and Cosmetic Act describes the conditions that must be satisfied for human drug products compounded by a licensed pharmacist to be exempt from GMP, labeling and approval requirements. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-24828.pdf?ref=fdaweb.com).